Huband M D, Cohen M A, Meservey M A, Roland G E, Yoder S L, Dazer M E, Domagala J M
Department of Therapeutics, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, Michigan 48105.
Antimicrob Agents Chemother. 1993 Dec;37(12):2563-70. doi: 10.1128/AAC.37.12.2563.
PD 138312 and PD 140248 are new quinolones with high in vitro activities against a wide spectrum of bacterial species, notably including gram-positive isolates. The respective MICs (in micrograms per milliliter) of PD 138312 and PD 140248 capable of inhibiting > or = 90% of the strains were < or = 0.06 and < or = 0.06 for oxacillin-susceptible and -resistant staphylococci, streptococci (including Streptococcus pyogenes, S. agalactiae, S. pneumoniae, and viridans group streptococci), Haemophilus influenzae, Moraxella catarrhalis, and Neisseria gonorrhoeae; 0.125 and 0.03 for Legionella pneumophila; 0.25 and 0.125 for Listeria monocytogenes; 0.25 and 0.25 for Enterococcus faecalis; 0.5 and 0.06 for anaerobic gram-positive cocci; 0.5 and 0.25 for Acinetobacter spp.; 0.5 and 0.5 for members of the family Enterobacteriaceae (excluding Serratia marcescens); 2 and 0.5 for Bacteroides fragilis; 2 and 2 for Serratia marcescens and ciprofloxacin-resistant staphylococci; and 8 and 4 for Pseudomonas aeruginosa.
PD 138312和PD 140248是新型喹诺酮类药物,对多种细菌具有高体外活性,特别是包括革兰氏阳性菌分离株。对于能够抑制≥90%菌株生长的情况,PD 138312和PD 140248的最低抑菌浓度(以微克/毫升计)分别为:对苯唑西林敏感和耐药的葡萄球菌、链球菌(包括化脓性链球菌、无乳链球菌、肺炎链球菌和草绿色链球菌)、流感嗜血杆菌、卡他莫拉菌和淋病奈瑟菌,≤0.06和≤0.06;对嗜肺军团菌,0.125和0.03;对单核细胞增生李斯特菌,0.25和0.125;对粪肠球菌,0.25和0.25;对厌氧革兰氏阳性球菌,0.5和0.06;对不动杆菌属,0.5和0.25;对肠杆菌科成员(不包括粘质沙雷菌),0.5和0.5;对脆弱拟杆菌,2和0.5;对粘质沙雷菌和耐环丙沙星葡萄球菌,2和2;对铜绿假单胞菌,8和4。